tetano
Editor, Senior Moderator
J Clin Med
. 2023 Sep 13;12(18):5953.
doi: 10.3390/jcm12185953. Sodium Valproate Use in Japanese Patients with Schizophrenia and Coronavirus Disease Is Associated with an Increased Risk of Pneumonia
Yusuke Arai[SUP] 1 2 [/SUP], Daimei Sasayama[SUP] 1 [/SUP], Akira Kuraishi[SUP] 2 [/SUP], Reiko Sahara[SUP] 2 [/SUP], Shiho Murata[SUP] 2 [/SUP], Akira Tanaka[SUP] 2 [/SUP], Kotaro Amemiya[SUP] 2 [/SUP], Nobuteru Usuda[SUP] 2 [/SUP], Kazuaki Kuraishi[SUP] 2 [/SUP], Shinsuke Washizuka[SUP] 1 [/SUP]
Affiliations
Schizophrenia is a known risk factor for coronavirus disease (COVID-19) infection and severity, and certain psychotropic drugs have been linked to increased mortality in infected patients with schizophrenia. However, little evidence exists regarding this risk. We retrospectively examined the association between mood stabilizers and the risk of pneumonia in patients with schizophrenia. This study included 99 patients with schizophrenia or schizoaffective disorder who were infected with COVID-19 in 2022 and met the inclusion criteria. After conducting propensity score matching to align patient backgrounds and concomitant medications, we assessed the impact of mood stabilizers, specifically sodium valproate, on the risk of pneumonia development. Univariate analysis revealed that patients with schizophrenia and COVID-19 who developed pneumonia were more likely to be older (64.5 [14.2] vs. 57.4 [11.5] years, p = 0.008) and using sodium valproate (44.4% vs. 16.7%, p = 0.004). Even after propensity score matching, patients who developed pneumonia were still more likely to be receiving sodium valproate than not (58.8% vs. 20.0%, p = 0.003). Sodium valproate use may be a risk factor for the development of pneumonia in patients with chronic schizophrenia who are infected with COVID-19 during long-term hospitalization.
Keywords: COVID-19; mood stabilizer; pneumonia; schizophrenia; sodium valproate.
. 2023 Sep 13;12(18):5953.
doi: 10.3390/jcm12185953. Sodium Valproate Use in Japanese Patients with Schizophrenia and Coronavirus Disease Is Associated with an Increased Risk of Pneumonia
Yusuke Arai[SUP] 1 2 [/SUP], Daimei Sasayama[SUP] 1 [/SUP], Akira Kuraishi[SUP] 2 [/SUP], Reiko Sahara[SUP] 2 [/SUP], Shiho Murata[SUP] 2 [/SUP], Akira Tanaka[SUP] 2 [/SUP], Kotaro Amemiya[SUP] 2 [/SUP], Nobuteru Usuda[SUP] 2 [/SUP], Kazuaki Kuraishi[SUP] 2 [/SUP], Shinsuke Washizuka[SUP] 1 [/SUP]
Affiliations
- PMID: 37762894
- DOI: 10.3390/jcm12185953
Schizophrenia is a known risk factor for coronavirus disease (COVID-19) infection and severity, and certain psychotropic drugs have been linked to increased mortality in infected patients with schizophrenia. However, little evidence exists regarding this risk. We retrospectively examined the association between mood stabilizers and the risk of pneumonia in patients with schizophrenia. This study included 99 patients with schizophrenia or schizoaffective disorder who were infected with COVID-19 in 2022 and met the inclusion criteria. After conducting propensity score matching to align patient backgrounds and concomitant medications, we assessed the impact of mood stabilizers, specifically sodium valproate, on the risk of pneumonia development. Univariate analysis revealed that patients with schizophrenia and COVID-19 who developed pneumonia were more likely to be older (64.5 [14.2] vs. 57.4 [11.5] years, p = 0.008) and using sodium valproate (44.4% vs. 16.7%, p = 0.004). Even after propensity score matching, patients who developed pneumonia were still more likely to be receiving sodium valproate than not (58.8% vs. 20.0%, p = 0.003). Sodium valproate use may be a risk factor for the development of pneumonia in patients with chronic schizophrenia who are infected with COVID-19 during long-term hospitalization.
Keywords: COVID-19; mood stabilizer; pneumonia; schizophrenia; sodium valproate.